CR10938A - Efectos combinados del topiramato y el ondansetron sobre el consumo de alcohol - Google Patents

Efectos combinados del topiramato y el ondansetron sobre el consumo de alcohol

Info

Publication number
CR10938A
CR10938A CR10938A CR10938A CR10938A CR 10938 A CR10938 A CR 10938A CR 10938 A CR10938 A CR 10938A CR 10938 A CR10938 A CR 10938A CR 10938 A CR10938 A CR 10938A
Authority
CR
Costa Rica
Prior art keywords
topiramate
ondansetron
alcohol
consumption
combined effects
Prior art date
Application number
CR10938A
Other languages
English (en)
Inventor
Bankole A Johnson
Nassima Ait-Daoud Touririne
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Publication of CR10938A publication Critical patent/CR10938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
CR10938A 2006-12-19 2009-07-17 Efectos combinados del topiramato y el ondansetron sobre el consumo de alcohol CR10938A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87566806P 2006-12-19 2006-12-19
US89852807P 2007-01-31 2007-01-31
US93103107P 2007-05-21 2007-05-21

Publications (1)

Publication Number Publication Date
CR10938A true CR10938A (es) 2010-01-11

Family

ID=39537067

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10938A CR10938A (es) 2006-12-19 2009-07-17 Efectos combinados del topiramato y el ondansetron sobre el consumo de alcohol

Country Status (8)

Country Link
US (1) US20100041689A1 (es)
EP (2) EP2124909A4 (es)
JP (1) JP2010513569A (es)
AU (1) AU2007333656A1 (es)
CA (1) CA2673481A1 (es)
CR (1) CR10938A (es)
MX (1) MX2009006672A (es)
WO (1) WO2008077092A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2677205A1 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
CA2697990A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
CA2716498C (en) 2008-02-28 2020-12-22 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
US9226918B2 (en) 2008-12-04 2016-01-05 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
EP2521546A4 (en) * 2010-01-07 2013-06-26 Vivus Inc TREATMENT OF THE OBSTRUCTIVE SLEEP APNEO SYNDROME COMBINED WITH ANTIBODY ANTIBODY AND AN ADDITIONAL ACTIVE SUBSTANCE
LT2801625T (lt) 2010-07-02 2018-03-12 University Of Virginia Patent Foundation Molekulinis genetinis būdas, skirtas priklausomybės nuo alkoholio ir narkotikų gydymui ir diagnozavimui
US20130072516A1 (en) * 2011-09-07 2013-03-21 Eagle Advancement Institute Llc Method of alcohol cessation and treatment
EA027743B1 (ru) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
CN107406369B (zh) 2014-12-09 2021-01-15 以西结·戈兰 放纵行为调节剂
CN114903134A (zh) 2014-12-09 2022-08-16 以西结·戈兰 酒精饮料替代品
EP3273952B1 (en) 2015-03-26 2022-06-15 Sen-Jam Pharmaceutical LLC Combination of naproxen and fexofenadine to inhibit symptoms associated with veisalgia
AU2019376633A1 (en) * 2018-11-06 2021-05-20 Purdue Pharma L.P. Compositions and methods for opioid antagonist delivery
MX2021013413A (es) * 2019-05-02 2022-02-11 Closed Loop Medicine Ltd Métodos y sistemas para proporcionar medicina personalizada a un paciente.
US20220117916A1 (en) * 2020-10-19 2022-04-21 SafeRx Pharmaceuticals, LLC Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH603545A5 (es) 1972-04-20 1978-08-31 Merz & Co
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5550021A (en) * 1990-02-07 1996-08-27 Board Of Regents, The University Of Texas System Allelic diagnosis of susceptibility to compulsive disorder
DE4010079A1 (de) 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US20040167164A1 (en) * 1998-05-05 2004-08-26 Jose Pozuelo Compositions and methods for treating particular chemical addictions and mental illnesses
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
JP2002537326A (ja) 1999-02-24 2002-11-05 ユニヴァーシティ・オブ・シンシナティ 衝動調節障害の治療のためのスルファメート誘導体の使用
WO2002028275A2 (en) * 2000-09-29 2002-04-11 New Health Sciences, Inc. Systems and methods for investigating blood flow
US7122308B2 (en) * 2001-02-16 2006-10-17 Centre For Addiction And Mental Health Detection of antidepressant induced mania
US7033771B2 (en) * 2001-05-08 2006-04-25 Takeda Pharmaceutical Company Limited Use of insulin response modulators in the treatment of diabetes and insulin resistance
EP1262196A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
HUP0401022A3 (en) * 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
US20030100479A1 (en) * 2001-08-21 2003-05-29 Dow David J. Gene polymorphisms and response to treatment
US20060173064A1 (en) 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US20030114475A1 (en) * 2001-10-31 2003-06-19 Addiction Therapies, Inc. Methods for the treatment of addiction
SI2316456T1 (sl) * 2003-04-29 2017-10-30 Orexigen Therapeutics, Inc. Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7163969B2 (en) * 2003-10-14 2007-01-16 Stockhausen, Inc. Superabsorbent polymer aqueous paste and coating
US20050245461A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
CN2722428Y (zh) 2004-07-21 2005-08-31 上海正贝照明电器有限公司 镇流器内藏式一体化节能灯
DK1928438T3 (da) * 2005-09-26 2013-04-22 Avigen Inc Anvendelse af ibudilast til behandling af stofafhængighed
US20070292880A1 (en) * 2006-05-05 2007-12-20 Robert Philibert Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
CA2677205A1 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
US20080228700A1 (en) * 2007-03-16 2008-09-18 Expanse Networks, Inc. Attribute Combination Discovery
WO2009026381A2 (en) * 2007-08-21 2009-02-26 University Of Virginia Patent Foundation Method, computer program product and system for individual assessment of alcohol sensitivity
CA2697990A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
CA2716498C (en) * 2008-02-28 2020-12-22 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
US20090269773A1 (en) * 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
EP2425013A1 (en) * 2009-05-01 2012-03-07 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism

Also Published As

Publication number Publication date
EP2556830A1 (en) 2013-02-13
WO2008077092A3 (en) 2008-08-14
WO2008077092A2 (en) 2008-06-26
EP2124909A2 (en) 2009-12-02
AU2007333656A1 (en) 2008-06-26
EP2124909A4 (en) 2010-03-31
WO2008077092A8 (en) 2009-08-20
US20100041689A1 (en) 2010-02-18
MX2009006672A (es) 2009-10-26
CA2673481A1 (en) 2008-06-26
JP2010513569A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
CR10938A (es) Efectos combinados del topiramato y el ondansetron sobre el consumo de alcohol
CR10847A (es) Compuesto heteromonociclico y uso del mismo
BRPI0922976A2 (pt) dispositivo e biópsia com câmaras teciduais distintas
BRPI0820483A2 (pt) Variantes de glicoamilase com propriedades alteradas
BRPI0908768A2 (pt) Variantes de olfa-amilase de ts23 com propriedades alteradas
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BRPI0819573A2 (pt) Composição e artigo
BRPI0817298A2 (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas
BRPI1009863A2 (pt) cânula com câmera e iluminação integrada
BRPI0817853A2 (pt) Variantes de glucoamilase com propriedades alteradas
FI20095084A0 (fi) Komposiitti ja sen käyttö
BRPI0918328A2 (pt) composição e artigo
BRPI0913807A2 (pt) composição e artigo
DE502008001632D1 (de) Karosserieaufbau
BRPI0721216A2 (pt) Composições de acetaminofen com efeitos colaterais minimizados e hepatotoxidez reduzida
BRPI0817974A2 (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas.
BRPI0922832A2 (pt) nonapeptídeo com atividade antitumor
NO20083139L (no) Anvendelse av hyllebærekstrakt
DE502007002482D1 (de) Injektor
BRPI0816284A2 (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas
BRPI0812584A2 (pt) Composições inseticidas com efeito melhorado
DK2310037T3 (da) Conglutin-gamma as-medikament og -kosttilskudpatentkrav
ATE521389T1 (de) Schutzbekleidung
IT1391436B1 (it) Dispositivo portacerotti tascabile con specchio interno
PL120663U1 (pl) Komora kriogeniczna